AZN: Enhertu Gets US Breakthrough Therapy Designation For HER2 Low/Ultralow Metastatic Breast Cancer

(RTTNews) - Daiichi Sankyo (DSKYF.PK) and AstraZeneca's (AZN.L, AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation or BTD in the U.S. for the treatment of unresectable or metastatic hormone receptor positive HER2 low or HER2 ultralow https://www.nasdaq.com/articles/azn-enhertu-gets-us-breakthrough-therapy-designation-her2-low-ultralow-metastatic-breast